CA3006388C - Thermostable fgf2 polypeptide, use thereof - Google Patents

Thermostable fgf2 polypeptide, use thereof Download PDF

Info

Publication number
CA3006388C
CA3006388C CA3006388A CA3006388A CA3006388C CA 3006388 C CA3006388 C CA 3006388C CA 3006388 A CA3006388 A CA 3006388A CA 3006388 A CA3006388 A CA 3006388A CA 3006388 C CA3006388 C CA 3006388C
Authority
CA
Canada
Prior art keywords
fgf2
amino acid
cells
polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3006388A
Other languages
English (en)
French (fr)
Other versions
CA3006388A1 (en
Inventor
Petr Dvorak
Pavel Krejci
Lukas BALEK
Livia EISELLEOVA
Zaneta KONECNA
Pavel DVORAK
David Bednar
Jan Brezovsky
Eva SEBESTOVA
Radka Chaloupkova
Veronika Stepankova
Pavel VANACEK
Zbynek Prokop
Jiri Damborsky
Michaela BOSAKOVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enantis SRO
Masarykova Univerzita
Original Assignee
Enantis SRO
Masarykova Univerzita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enantis SRO, Masarykova Univerzita filed Critical Enantis SRO
Publication of CA3006388A1 publication Critical patent/CA3006388A1/en
Application granted granted Critical
Publication of CA3006388C publication Critical patent/CA3006388C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Birds (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
CA3006388A 2015-11-27 2016-10-03 Thermostable fgf2 polypeptide, use thereof Active CA3006388C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15196802 2015-11-27
EP15196802.1 2015-11-27
PCT/EP2016/073567 WO2017089016A1 (en) 2015-11-27 2016-10-03 Thermostable fgf2 polypeptide, use thereof

Publications (2)

Publication Number Publication Date
CA3006388A1 CA3006388A1 (en) 2017-06-01
CA3006388C true CA3006388C (en) 2023-05-09

Family

ID=54754475

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3006388A Active CA3006388C (en) 2015-11-27 2016-10-03 Thermostable fgf2 polypeptide, use thereof

Country Status (11)

Country Link
US (1) US11746135B2 (https=)
EP (1) EP3380508B1 (https=)
JP (1) JP7131772B2 (https=)
KR (1) KR102650035B1 (https=)
AU (1) AU2016359722B2 (https=)
CA (1) CA3006388C (https=)
ES (1) ES2824479T3 (https=)
LT (1) LT3380508T (https=)
PL (1) PL3380508T3 (https=)
SG (1) SG11201804402WA (https=)
WO (1) WO2017089016A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022548776A (ja) * 2019-09-19 2022-11-21 ノースウェスタン ユニバーシティ ヒト人工多能性幹細胞のための費用効果の高い培地およびプロトコル
CN114746436B (zh) * 2019-11-25 2024-07-02 韩国海洋科学技术院 改善温度稳定性和蛋白酶抗性的fgf2多肽及其用途
KR102428940B1 (ko) * 2019-11-25 2022-08-03 한국해양과학기술원 온도안정성 및 단백질 분해효소 저항성을 향상시킨 fgf2 폴리펩타이드 및 그 용도
CZ309550B6 (cs) * 2021-06-15 2023-04-05 Enantis s.r.o Termostabilní polypeptid na bázi FGF18 a jeho použití
GB2616475A (en) * 2022-03-11 2023-09-13 Multus Biotechnology Ltd Engineered fibroblast growth factor variants
JP2025538574A (ja) * 2022-11-25 2025-11-28 ビーティーエル ヘルスケア テクノロジーズ エー．エス． 安定性が向上したｆｇｆ－２ポリペプチド、ｆｇｆ－２ポリペプチドを調製するための方法及びその使用
KR20240173282A (ko) * 2023-06-02 2024-12-11 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포 유래 엑소좀의 제조방법
KR20240173283A (ko) * 2023-06-02 2024-12-11 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포의 배양방법
WO2025141173A1 (en) 2023-12-28 2025-07-03 Meatable B.V. Methods of increasing differentiation and/or fat accumulation in cells
WO2025186217A1 (en) 2024-03-05 2025-09-12 The Cultivated B. Gmbh Animal collagen from non-animal sources
EP4613865A1 (en) 2024-03-05 2025-09-10 The Cultivated B. GmbH Animal collagen from non-animal sources

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614137B2 (en) 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US5202311A (en) 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5143829A (en) 1990-03-29 1992-09-01 California Biotechnology Inc. High level expression of basic fibroblast growth factor having a homogeneous n-terminus
WO1995008630A1 (en) * 1993-09-24 1995-03-30 American Cyanamid Company Surface loop structural analogues of fibroblast growth factors
CA2281925A1 (en) 1997-02-26 1998-09-03 Ciblex Corporation Inhibitors of leaderless protein export
US7754686B2 (en) 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1444995A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) FGF-2 derived proteins for the preparation of biomaterials or medical devices such as stents
US7816140B2 (en) * 2005-06-14 2010-10-19 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
US20070212332A1 (en) * 2005-08-11 2007-09-13 Department Of Veterans Affairs Methods for accelerating bone repair
EP2083846B1 (en) * 2006-09-28 2015-07-15 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
CA2802896C (en) 2010-07-01 2021-05-11 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
US9169309B2 (en) * 2011-03-01 2015-10-27 Humanzyme Inc. Thermostable variants of fibroblast growth factors
WO2013082196A1 (en) 2011-11-28 2013-06-06 The Regents Of The University Of California bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF
WO2013090911A1 (en) 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Method for supporting human pluri potent stem cell cultures comprising culturing the cells in a medium comprising thermostable fgf - 1 proteins
WO2013090919A1 (en) * 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Fgf-2 having enhanced stability
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
EP2930181B1 (en) * 2014-04-07 2017-10-11 Miltenyi Biotec GmbH Fibroblast growth factor muteins with increased activity

Also Published As

Publication number Publication date
EP3380508B1 (en) 2020-07-22
EP3380508A1 (en) 2018-10-03
PL3380508T3 (pl) 2021-07-12
SG11201804402WA (en) 2018-06-28
BR112018010676A2 (pt) 2019-04-09
US20200270320A1 (en) 2020-08-27
JP7131772B2 (ja) 2022-09-06
AU2016359722B2 (en) 2020-09-17
CN108779158A (zh) 2018-11-09
US11746135B2 (en) 2023-09-05
JP2019500414A (ja) 2019-01-10
LT3380508T (lt) 2020-11-10
KR102650035B1 (ko) 2024-03-20
ES2824479T3 (es) 2021-05-12
KR20180080335A (ko) 2018-07-11
CA3006388A1 (en) 2017-06-01
WO2017089016A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
CA3006388C (en) Thermostable fgf2 polypeptide, use thereof
AU2016359722A1 (en) Thermostable FGF2 polypeptide, use thereof
JP2022008319A (ja) プロトキシン－ｉｉ変異体及びその使用方法
CN117843763B (zh) 生物合成人体结构性材料xvii型胶原蛋白的方法
JP2013515474A (ja) 組換え体ｈ因子ならびにそのバリアントおよびコンジュゲート
CN110950967A (zh) 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
JP2025516910A (ja) 生合成による人体構造性材料の製造方法
Ma et al. Cytotoxic potency of cardiotoxin from Naja sputatrix: development of a new cytolytic assay
Hecht et al. Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor-and heparin-binding interfaces
EP3168230B1 (en) Gdf-5 mutant for inducing cartilage formation
WO2000061755A2 (en) Secreted human proteins
KR20100085041A (ko) Ｓｄｆ-1계 글리코스아미노글리칸 길항제 및 그 사용 방법
CN108779158B (zh) 热稳定性fgf2多肽、其用途
BR112018010676B1 (pt) Polipeptídeo termoestável e meio de cultura
US12344666B2 (en) PDGF mutants and methods of use thereof
Shah Towards a structural understanding of the iRhom/ADAM17 complex
KR20250110924A (ko) 개선된 안정성을 갖는 fgf-2 폴리펩티드, fgf-2 폴리펩티드를 제조하는 방법 및 그의 용도
Schafer Extending the HECT Domain of HERC4 Improves Solubility and Catalysis
CA3238316A1 (en) Thermostable fgf10 polypeptide or fragment thereof and use thereof
CZ309550B6 (cs) Termostabilní polypeptid na bázi FGF18 a jeho použití
Chiu Study of Structural Relationship Between Human Ribosomal Proteins P1 and P2
Sebastian Samuel et al. Probing protease sensitivity of recombinant human erythropoietin reveals α3–α4 inter‐helical loop as a stability determinant
HK1156329B (en) Modified peptide of human acidic fibroblast growth factor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191018

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240812

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240812

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250709

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250709